Brief: Transgene Says Its Novel Therapeutic Cancer Vaccine TG4001 Can Induce T-Cell Responses Against HPV16 Antigens

Transgene SA

05/06/2023 06:43

June 5 (Reuters) - Transgene Sa  TRNG.PA :
    * TRANSGENE PRESENTS IMMUNOLOGICAL DATA DEMONSTRATING THAT
TG4001,
A NOVEL THERAPEUTIC CANCER VACCINE, CAN INDUCE T-CELL RESPONSES
AGAINST HPV16 ANTIGENS IN THE ONGOING PHASE II TRIAL AT ASCO
2023
    * ANTICIPATES THAT LAST PATIENT WILL BE RANDOMIZED IN
CURRENT
PHASE II CLINICAL STUDY IN FIRST HALF OF 2024
    * TRANSGENE IS PREPARING FOR A POTENTIALLY REGISTRATIONAL
STUDY
    * FINAL RESULTS WILL BE COMMUNICATED IN 2024
    * PATIENTS WITH COMPLETE OBJECTIVE RESPONSE SHOWED STRONG
VACCINE-INDUCED IMMUNOREACTIVITY
    * 11 OF 13 PATIENTS WITH AN IMMUNE RESPONSE HAD EITHER
STABLE
DISEASE, PARTIAL OR COMPLETE TUMOR RESPONSE ACCORDING TO RECIST
CRITERIA.
    * PREPARING FOR A PLANNED POTENTIALLY REGISTRATIONAL TRIAL
IN AN
HPV-POSITIVE INDICATION

Source text for Eikon:  ID:nBw5zqGSRa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))